Clinical Efficacy and Safety Evaluation of Teneligliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Empaglyflozin 25 mg and Metformin

Inclusion Criteria: * Patients with Type II diabetes mellitus aged 19 years or older * Subjects with 7.0%≤HbA1c≤10.5% at screening visit * Subjects with fasting plasma glucose ≤ 270mg/dL at screening visit Exclusion Criteria: * Subjects with type 1 diabetes mellitus or secondary diabetes * Subjects with history of diabetic ketoacidosis, diabetic coma or pre-coma, lactic acidosis, and acute or chronic acidosis within 6 months prior to the screening visit * Subjects who have been administered with weight-loss drug (e.g., orlistat, phentermine/topiramate, lorcaserin) * Body mass index greater than 40 kg/m2 at the screening visit * Subjects with heart failure (Class III-IV of NYHA classification) or arrhythmia that requires treatment